The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...

Eli Lilly and Novo Nordisk have been top stocks for investors who are bullish on the weight loss market. However, fellow ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...

Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter ...

Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” ...

On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

In a report released today, Peter Verdult from Citi initiated coverage with a Buy rating on Eli Lilly & Co (LLY – Research Report) ...

We’re maintaining our $580 fair value estimate for Eli Lilly and DKK 600/$86 fair value estimates for Novo Nordisk after analyzing the public and private competitive landscape for obesity drugs ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...